Cargando…
The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol
BACKGROUND: Uncomplicated lower urinary tract infections (LUTI) are very common, and presumably around 200,000 female patients are treated for this annually in Denmark. The current Danish national clinical practice guidelines recommend pivmecillinam as a first-line drug (i.e., 400 mg t.i.d. for 3 da...
Autores principales: | Jansåker, Filip, Frimodt-Møller, Niels, Bjerrum, Lars, Dahl Knudsen, Jenny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134065/ https://www.ncbi.nlm.nih.gov/pubmed/27905884 http://dx.doi.org/10.1186/s12879-016-2022-0 |
Ejemplares similares
-
Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial()
por: Jansåker, Filip, et al.
Publicado: (2019) -
Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus—Cumulative Observational Data from Four Recent Clinical Studies
por: Jansåker, Filip, et al.
Publicado: (2019) -
Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study
por: Jansåker, Filip, et al.
Publicado: (2019) -
1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021) -
Mutational change of CTX‐M‐15 to CTX‐M‐127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient
por: Nielsen, Karen Leth, et al.
Publicado: (2019)